Ask anyone in a research forum which growth-hormone peptides to look at, and within one reply you will hear the same pairing: CJC-1295 and Ipamorelin. They are almost never discussed alone. There is an actual pharmacological reason for that — the two do different jobs that happen to line up, and understanding the mechanism is what separates the people who know what they are researching from the people repeating a stack they saw on Reddit.
What CJC-1295 does
CJC-1295 is an analog of growth-hormone-releasing hormone (GHRH) — the body’s own upstream signal telling the pituitary to release GH. Its clever trick is longevity: a modification lets it bind to albumin in the blood, dramatically extending its half-life. In a landmark study of healthy adults, a single injection raised growth hormone and IGF-1 and kept them elevated for days, not minutes. In plain terms, CJC-1295 raises the baseline from which GH is released.
What Ipamorelin does
Ipamorelin works on a completely different receptor — it is a ghrelin-receptor agonist, a growth-hormone secretagogue that triggers a sharp, clean pulse of GH release. What made it notable when first described in 1998 is its selectivity: it was the first secretagogue of its kind shown to release GH without meaningfully raising cortisol, prolactin or other hormones that older compounds disturbed. A pulse, without the hormonal noise.
Why researchers pair them
This is the elegant part. CJC-1295 raises the GHRH tone — the standing invitation for GH release — while Ipamorelin delivers the acute pulse through a separate pathway. Because they act on two different receptors, their effects are thought to be complementary rather than redundant: one sets the stage, the other triggers the release. The result, in theory, mimics the body’s own pulsatile GH pattern more closely than either compound alone, which is why the CJC-1295/Ipamorelin blend is the single most-researched GH-peptide combination.
One raises the baseline, the other fires the pulse. Two receptors, one coordinated signal — that is the whole logic of the stack.TrueLabs Research Team
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | Ghrelin-receptor agonist (secretagogue) |
| Effect | Sustained elevation | Sharp pulse |
| Signature trait | Long half-life (albumin binding) | High selectivity, low cortisol/prolactin |
| Role in the stack | Sets the baseline | Triggers release |
The evidence, honestly
The individual molecules are genuinely well-characterised — CJC-1295’s half-life study and Ipamorelin’s selectivity work are real, published pharmacology. What is thinner is controlled human research on the combination for the body-composition outcomes people chase. Most of what circulates about the stack’s real-world results is anecdotal. The mechanism is sound; the human outcome data is still catching up. For the bigger picture on GH peptides and muscle, see the best peptides for muscle growth.
Researching GH secretagogues? The blend ships with third-party purity data.
FAQ
Why are CJC-1295 and Ipamorelin used together?
They act on two different receptors. CJC-1295 (a GHRH analog) raises the sustained GH baseline, while Ipamorelin (a ghrelin-receptor agonist) triggers a sharp pulse. The effects are considered complementary, mimicking natural pulsatile GH release.
What makes Ipamorelin different from older secretagogues?
Selectivity. When first described in 1998 it was notable for releasing growth hormone without meaningfully raising cortisol or prolactin, which older compounds disturbed.
Is there human data on the combination?
The individual molecules are well-characterised in published pharmacology. Controlled human research on the combination specifically is limited, and much of what circulates is anecdotal.
Is the blend approved for use?
No. It is sold strictly for laboratory research use and is not an approved medicine.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.